Gina Eagle

1.2k total citations
39 papers, 598 citations indexed

About

Gina Eagle is a scholar working on Epidemiology, Infectious Diseases and Organic Chemistry. According to data from OpenAlex, Gina Eagle has authored 39 papers receiving a total of 598 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Epidemiology, 13 papers in Infectious Diseases and 9 papers in Organic Chemistry. Recurrent topics in Gina Eagle's work include Mycobacterium research and diagnosis (20 papers), Tuberculosis Research and Epidemiology (12 papers) and Eosinophilic Esophagitis (7 papers). Gina Eagle is often cited by papers focused on Mycobacterium research and diagnosis (20 papers), Tuberculosis Research and Epidemiology (12 papers) and Eosinophilic Esophagitis (7 papers). Gina Eagle collaborates with scholars based in United States, United Kingdom and Switzerland. Gina Eagle's co-authors include Renu Gupta, Kenneth N. Olivier, Lynn Cawkwell, Kevin Winthrop, David E. Griffith, Michael Lind, Richard J. Wallace, Barbara A. Brown‐Elliott, John P. McGinnis and Stephen J. Ruoss and has published in prestigious journals such as Blood, Gastroenterology and Hepatology.

In The Last Decade

Gina Eagle

38 papers receiving 571 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gina Eagle United States 13 243 189 112 110 105 39 598
Ali Rıza Köksal Türkiye 12 156 0.6× 58 0.3× 27 0.2× 116 1.1× 45 0.4× 38 537
Xingye Wu China 17 191 0.8× 232 1.2× 11 0.1× 396 3.6× 56 0.5× 47 904
Allison Vitsky United States 14 54 0.2× 53 0.3× 63 0.6× 170 1.5× 46 0.4× 27 540
Hassan Ehteram Iran 11 79 0.3× 71 0.4× 12 0.1× 115 1.0× 54 0.5× 32 486
Michael Cooreman United States 13 417 1.7× 72 0.4× 18 0.2× 254 2.3× 59 0.6× 23 910
Bing Wei China 19 218 0.9× 142 0.8× 5 0.0× 256 2.3× 69 0.7× 42 755
Anastasia Slobodnick United States 5 48 0.2× 55 0.3× 10 0.1× 250 2.3× 31 0.3× 10 577
M A Jay United States 10 356 1.5× 206 1.1× 5 0.0× 148 1.3× 149 1.4× 11 806
Haiying Yan China 12 82 0.3× 74 0.4× 8 0.1× 163 1.5× 55 0.5× 35 474
Fenghua Peng China 12 129 0.5× 155 0.8× 10 0.1× 155 1.4× 56 0.5× 49 474

Countries citing papers authored by Gina Eagle

Since Specialization
Citations

This map shows the geographic impact of Gina Eagle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gina Eagle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gina Eagle more than expected).

Fields of papers citing papers by Gina Eagle

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gina Eagle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gina Eagle. The network helps show where Gina Eagle may publish in the future.

Co-authorship network of co-authors of Gina Eagle

This figure shows the co-authorship network connecting the top 25 collaborators of Gina Eagle. A scholar is included among the top collaborators of Gina Eagle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gina Eagle. Gina Eagle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Winthrop, Kevin, Scott Beegle, Guenther Koehne, et al.. (2022). Opaganib in Coronavirus Disease 2019 Pneumonia: Results of a Randomized, Placebo-Controlled Phase 2a Trial. Open Forum Infectious Diseases. 9(7). ofac232–ofac232. 10 indexed citations
2.
Dellon, Evan S., Alfredo J. Lucendo, Christoph Schlag, et al.. (2022). Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial. Clinical Gastroenterology and Hepatology. 20(11). 2485–2494.e15. 34 indexed citations
3.
Eagle, Gina, John Herbert, Jianguo Zhuang, et al.. (2021). Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells. Scientific Reports. 11(1). 2932–2932. 7 indexed citations
4.
Dellon, Evan S., Jeffrey M. Rohay, Ashley F. Slagle, et al.. (2020). Mo1184 AN EPISODE-BASED PATIENT-REPORTED OUTCOME MEASURE OF DYSPHAGIA EXPERIENCE IS FEASIBLE AND NOT BURDENSOME FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS. Gastroenterology. 158(6). S–818. 1 indexed citations
5.
6.
7.
Griffith, David E., Gina Eagle, Rachel Thomson, et al.. (2018). Randomized Phase 3 Trial of Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) in Adult Patients. American Journal of Respiratory and Critical Care Medicine. 197. 1 indexed citations
8.
Winthrop, Kevin, Gina Eagle, Rachel Thomson, et al.. (2018). Six-Minute Walk Test (6MWT) Performance in Adult Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC). American Journal of Respiratory and Critical Care Medicine. 197.
9.
Marras, Theodore K., Christopher Vinnard, Quanwu Zhang, et al.. (2018). Relative risk of all-cause mortality in patients with nontuberculous mycobacterial lung disease in a US managed care population. Respiratory Medicine. 145. 80–88. 41 indexed citations
10.
Eagle, Gina, Karen Brown, & R. Andres Floto. (2017). Examining the Effect of Residual Amikacin on Sputum Culture for Nontuberculous Mycobacteria. American Journal of Respiratory and Critical Care Medicine. 197(2). 267–269. 2 indexed citations
11.
12.
Olivier, Kenneth N., David E. Griffith, Gina Eagle, et al.. (2016). Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 195(6). 814–823. 169 indexed citations
13.
Eagle, Gina, Jianguo Zhuang, Rosalind E. Jenkins, et al.. (2015). Total Proteome Analysis Identifies Migration Defects as a Major Pathogenetic Factor in Immunoglobulin Heavy Chain Variable Region (IGHV)-unmutated Chronic Lymphocytic Leukemia. Molecular & Cellular Proteomics. 14(4). 933–945. 27 indexed citations
14.
15.
Bilton, Diana, T. Pressler, Isabelle Fajac, et al.. (2014). ANALYSIS OF LONG-TERM LIPOSOMAL AMIKACIN FOR INHALATION IN PATIENTS WITH CYSTIC FIBROSIS AND CHRONIC INFECTION FROM PSEUDOMONAS AERUGINOSA. Pediatric Pulmonology. 49. 317–318. 6 indexed citations
16.
Eagle, Gina, et al.. (2013). Proteomic (antibody microarray) exploration of the molecular mechanism of action of the specific COX-2 inhibitor DuP 697. International Journal of Oncology. 42(3). 1088–1092. 3 indexed citations
17.
Kashuba, Elena, Gina Eagle, James R Bailey, et al.. (2013). Proteomic analysis of B-cell receptor signaling in chronic lymphocytic leukaemia reveals a possible role for kininogen. Journal of Proteomics. 91. 478–485. 12 indexed citations
18.
Eagle, Gina, et al.. (2010). Biomarkers of chemotherapy resistance in breast cancer identified by proteomics: Current status. Cancer Letters. 294(1). 13–24. 30 indexed citations
19.
Nordberg, Agneta, Taher Darreh‐Shori, Elaine R. Peskind, et al.. (2009). Different Cholinesterase Inhibitor Effects on CSF Cholinesterases in Alzheimer Patients. Current Alzheimer Research. 6(1). 4–14. 67 indexed citations
20.
O’Kane, Sara L., Gina Eagle, John Greenman, Michael Lind, & Lynn Cawkwell. (2009). COX-2 specific inhibitors enhance the cytotoxic effects of pemetrexed in mesothelioma cell lines. Lung Cancer. 67(2). 160–165. 25 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ali Rıza Köksal Breakdown of academic impact, for papers by Xingye Wu Breakdown of academic impact, for papers by Allison Vitsky Breakdown of academic impact, for papers by Hassan Ehteram Breakdown of academic impact, for papers by Michael Cooreman Breakdown of academic impact, for papers by Bing Wei Breakdown of academic impact, for papers by Anastasia Slobodnick Breakdown of academic impact, for papers by M A Jay Breakdown of academic impact, for papers by Haiying Yan Breakdown of academic impact, for papers by Fenghua Peng
Rankless by CCL
2026